Interleukin-1beta: An interleukin-1 subtype that is synthesized as an inactive membrane-bound pro-protein. Proteolytic processing of the precursor form by CASPASE 1 results in release of the active form of interleukin-1beta from the membrane.Hormone Antagonists: Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.beta 2-Microglobulin: An 11-kDa protein associated with the outer membrane of many cells including lymphocytes. It is the small subunit of the MHC class I molecule. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, csf, and urine of normal people, and to a much greater degree in the urine and plasma of patients with tubular proteinemia, renal failure, or kidney transplants.Dopamine Antagonists: Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.Receptors, Adrenergic, beta: One of two major pharmacologically defined classes of adrenergic receptors. The beta adrenergic receptors play an important role in regulating CARDIAC MUSCLE contraction, SMOOTH MUSCLE relaxation, and GLYCOGENOLYSIS.Excitatory Amino Acid Antagonists: Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists.Neurokinin-1 Receptor Antagonists: Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS.Interleukin 1 Receptor Antagonist Protein: A ligand that binds to but fails to activate the INTERLEUKIN 1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA.Narcotic Antagonists: Agents inhibiting the effect of narcotics on the central nervous system.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Histamine H2 Antagonists: Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.Muscarinic Antagonists: Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.Integrin beta3: An integrin beta subunit of approximately 85-kDa in size which has been found in INTEGRIN ALPHAIIB-containing and INTEGRIN ALPHAV-containing heterodimers. Integrin beta3 occurs as three alternatively spliced isoforms, designated beta3A-C.Rats, Sprague-Dawley: A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.GABA Antagonists: Drugs that bind to but do not activate GABA RECEPTORS, thereby blocking the actions of endogenous GAMMA-AMINOBUTYRIC ACID and GABA RECEPTOR AGONISTS.Nicotinic Antagonists: Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses.Histamine H1 Antagonists: Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.Piperidines: A family of hexahydropyridines.Purinergic P1 Receptor Antagonists: Compounds that bind to and block the stimulation of PURINERGIC P1 RECEPTORS.Histamine Antagonists: Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.Adenosine A2 Receptor Antagonists: Compounds that selectively bind to and block the activation of ADENOSINE A2 RECEPTORS.Purinergic P2 Receptor Antagonists: Compounds that bind to and block the stimulation of PURINERGIC P2 RECEPTORS.Adrenergic alpha-1 Receptor Antagonists: Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.Serotonin 5-HT3 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS.Rats, Wistar: A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.Serotonin 5-HT2 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Adenosine A1 Receptor Antagonists: Compounds that bind to and block the stimulation of ADENOSINE A1 RECEPTORS.Leukotriene Antagonists: A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.Cell Line: Established cell cultures that have the potential to propagate indefinitely.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Angiotensin Receptor Antagonists: Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.Adrenergic Antagonists: Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE.Interleukin-1: A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation.Receptors, Adrenergic, beta-2: A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The adrenergic beta-2 receptors are more sensitive to EPINEPHRINE than to NOREPINEPHRINE and have a high affinity for the agonist TERBUTALINE. They are widespread, with clinically important roles in SKELETAL MUSCLE; LIVER; and vascular, bronchial, gastrointestinal, and genitourinary SMOOTH MUSCLE.Integrin alpha5beta1: An integrin found in FIBROBLASTS; PLATELETS; MONOCYTES, and LYMPHOCYTES. Integrin alpha5beta1 is the classical receptor for FIBRONECTIN, but it also functions as a receptor for LAMININ and several other EXTRACELLULAR MATRIX PROTEINS.GABA-A Receptor Antagonists: Drugs that bind to but do not activate GABA-A RECEPTORS thereby blocking the actions of endogenous or exogenous GABA-A RECEPTOR AGONISTS.Binding, Competitive: The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.Adrenergic alpha-2 Receptor Antagonists: Drugs that bind to and block the activation of ADRENERGIC ALPHA-2 RECEPTORS.Radioligand Assay: Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders).Integrin beta4: Also known as CD104 antigen, this protein is distinguished from other beta integrins by its relatively long cytoplasmic domain (approximately 1000 amino acids vs. approximately 50). Five alternatively spliced isoforms have been described.Adrenergic beta-Antagonists: Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.Adrenergic alpha-Antagonists: Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.Integrin alpha6beta4: This intrgrin is a key component of HEMIDESMOSOMES and is required for their formation and maintenance in epithelial cells. Integrin alpha6beta4 is also found on thymocytes, fibroblasts, and Schwann cells, where it functions as a laminin receptor (RECEPTORS, LAMININ) and is involved in wound healing, cell migration, and tumor invasiveness.Integrin alpha4beta1: Integrin alpha4beta1 is a FIBRONECTIN and VCAM-1 receptor present on LYMPHOCYTES; MONOCYTES; EOSINOPHILS; NK CELLS and thymocytes. It is involved in both cell-cell and cell- EXTRACELLULAR MATRIX adhesion and plays a role in INFLAMMATION, hematopoietic cell homing and immune function, and has been implicated in skeletal MYOGENESIS; NEURAL CREST migration and proliferation, lymphocyte maturation and morphogenesis of the PLACENTA and HEART.Integrin beta Chains: Integrin beta chains combine with integrin alpha chains to form heterodimeric cell surface receptors. Integrins have traditionally been classified into functional groups based on the identity of one of three beta chains present in the heterodimer. The beta chain is necessary and sufficient for integrin-dependent signaling. Its short cytoplasmic tail contains sequences critical for inside-out signaling.beta 2-Glycoprotein I: A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.Propanolamines: AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives.Histamine H3 Antagonists: Drugs that selectively bind to but do not activate HISTAMINE H3 RECEPTORS. They have been used to correct SLEEP WAKE DISORDERS and MEMORY DISORDERS.Receptors, Adrenergic, beta-1: A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The adrenergic beta-1 receptors are equally sensitive to EPINEPHRINE and NOREPINEPHRINE and bind the agonist DOBUTAMINE and the antagonist METOPROLOL with high affinity. They are found in the HEART, juxtaglomerular cells, and in the central and peripheral nervous systems.Pyridines: Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.Integrin alpha2beta1: An integrin found on fibroblasts, platelets, endothelial and epithelial cells, and lymphocytes where it functions as a receptor for COLLAGEN and LAMININ. Although originally referred to as the collagen receptor, it is one of several receptors for collagen. Ligand binding to integrin alpha2beta1 triggers a cascade of intracellular signaling, including activation of p38 MAP kinase.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Adrenergic beta-Agonists: Drugs that selectively bind to and activate beta-adrenergic receptors.Ligands: A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)Receptors, Serotonin: Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action.Mice, Inbred C57BLReceptors, Endothelin: Cell surface proteins that bind ENDOTHELINS with high affinity and trigger intracellular changes which influence the behavior of cells.Guinea Pigs: A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research.Kinetics: The rate dynamics in chemical or physical systems.Adrenergic beta-2 Receptor Antagonists: Drugs that bind to and block the activation of ADRENERGIC BETA-2 RECEPTORS.Calcium Channel Blockers: A class of drugs that act by selective inhibition of calcium influx through cellular membranes.Receptors, N-Methyl-D-Aspartate: A class of ionotropic glutamate receptors characterized by affinity for N-methyl-D-aspartate. NMDA receptors have an allosteric binding site for glycine which must be occupied for the channel to open efficiently and a site within the channel itself to which magnesium ions bind in a voltage-dependent manner. The positive voltage dependence of channel conductance and the high permeability of the conducting channel to calcium ions (as well as to monovalent cations) are important in excitotoxicity and neuronal plasticity.Oligopeptides: Peptides composed of between two and twelve amino acids.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Integrins: A family of transmembrane glycoproteins (MEMBRANE GLYCOPROTEINS) consisting of noncovalent heterodimers. They interact with a wide variety of ligands including EXTRACELLULAR MATRIX PROTEINS; COMPLEMENT, and other cells, while their intracellular domains interact with the CYTOSKELETON. The integrins consist of at least three identified families: the cytoadhesin receptors(RECEPTORS, CYTOADHESIN), the leukocyte adhesion receptors (RECEPTORS, LEUKOCYTE ADHESION), and the VERY LATE ANTIGEN RECEPTORS. Each family contains a common beta-subunit (INTEGRIN BETA CHAINS) combined with one or more distinct alpha-subunits (INTEGRIN ALPHA CHAINS). These receptors participate in cell-matrix and cell-cell adhesion in many physiologically important processes, including embryological development; HEMOSTASIS; THROMBOSIS; WOUND HEALING; immune and nonimmune defense mechanisms; and oncogenic transformation.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Calcium: A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.Serotonin 5-HT1 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT1 RECEPTORS, thereby blocking the actions of SEROTONIN 5-HT1 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more of the specific 5-HT1 receptor subtypes.Binding Sites: The parts of a macromolecule that directly participate in its specific combination with another molecule.Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.Neurons: The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM.Peptide Fragments: Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.Drug Interactions: The action of a drug that may affect the activity, metabolism, or toxicity of another drug.Estrogen Antagonists: Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.Indoles: Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.Benzazepines: Compounds with BENZENE fused to AZEPINES.Antigens, CD29: Integrin beta-1 chains which are expressed as heterodimers that are noncovalently associated with specific alpha-chains of the CD49 family (CD49a-f). CD29 is expressed on resting and activated leukocytes and is a marker for all of the very late activation antigens on cells. (from: Barclay et al., The Leukocyte Antigen FactsBook, 1993, p164)Biphenyl CompoundsCricetinae: A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.Adenosine A3 Receptor Antagonists: Compounds that selectively bind to and block the activation of ADENOSINE A3 RECEPTORS.Sulfonamides: A group of compounds that contain the structure SO2NH2.Sialoglycoproteins: Glycoproteins which contain sialic acid as one of their carbohydrates. They are often found on or in the cell or tissue membranes and participate in a variety of biological activities.Receptors, Adrenergic, beta-3: A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The beta-3 adrenergic receptors are the predominant beta-adrenergic receptor type expressed in white and brown ADIPOCYTES and are involved in modulating ENERGY METABOLISM and THERMOGENESIS.CHO Cells: CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells.Receptor, Endothelin A: A subtype of endothelin receptor found predominantly in the VASCULAR SMOOTH MUSCLE. It has a high affinity for ENDOTHELIN-1 and ENDOTHELIN-2.Integrin alpha6beta1: A cell surface receptor mediating cell adhesion to the EXTRACELLULAR MATRIX and to other cells via binding to LAMININ. It is involved in cell migration, embryonic development, leukocyte activation and tumor cell invasiveness. Integrin alpha6beta1 is the major laminin receptor on PLATELETS; LEUKOCYTES; and many EPITHELIAL CELLS, and ligand binding may activate a number of signal transduction pathways. Alternative splicing of the cytoplasmic domain of the alpha6 subunit (INTEGRIN ALPHA6) results in the formation of A and B isoforms of the heterodimer, which are expressed in a tissue-specific manner.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Estrogen Receptor beta: One of the ESTROGEN RECEPTORS that has greater affinity for ISOFLAVONES than ESTROGEN RECEPTOR ALPHA does. There is great sequence homology with ER alpha in the DNA-binding domain but not in the ligand binding and hinge domains.Peptides, Cyclic: Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL).PiperazinesNaltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.Mice, Knockout: Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Receptors, Nicotinic: One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Pyrazoles: Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.Structure-Activity Relationship: The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.Gene Expression Regulation: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.Xanthines: Purine bases found in body tissues and fluids and in some plants.Purinergic P2X Receptor Antagonists: Compounds that bind to and block the stimulation of PURINERGIC P2X RECEPTORS. Included under this heading are antagonists for specific P2X receptor subtypes.Serotonin Receptor Agonists: Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS.Substance P: An eleven-amino acid neurotransmitter that appears in both the central and peripheral nervous systems. It is involved in transmission of PAIN, causes rapid contractions of the gastrointestinal smooth muscle, and modulates inflammatory and immune responses.Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.Glycogen Synthase Kinase 3: A glycogen synthase kinase that was originally described as a key enzyme involved in glycogen metabolism. It regulates a diverse array of functions such as CELL DIVISION, microtubule function and APOPTOSIS.Azepines: Seven membered heterocyclic rings containing a NITROGEN atom.Integrin alpha1beta1: Integrin alpha1beta1 functions as a receptor for LAMININ and COLLAGEN. It is widely expressed during development, but in the adult is the predominant laminin receptor (RECEPTORS, LAMININ) in mature SMOOTH MUSCLE CELLS, where it is important for maintenance of the differentiated phenotype of these cells. Integrin alpha1beta1 is also found in LYMPHOCYTES and microvascular endothelial cells, and may play a role in angiogenesis. In SCHWANN CELLS and neural crest cells, it is involved in cell migration. Integrin alpha1beta1 is also known as VLA-1 and CD49a-CD29.Transforming Growth Factor beta1: A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME.Purinergic Antagonists: Drugs that bind to and block the activation of PURINERGIC RECEPTORS.Serotonin: A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.PyrrolidinesQuinoxalinesElectric Stimulation: Use of electric potential or currents to elicit biological responses.Behavior, Animal: The observable response an animal makes to any situation.Cell Adhesion: Adherence of cells to surfaces or to other cells.Norepinephrine: Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.Phosphorylation: The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.Adrenergic beta-2 Receptor Agonists: Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.Enzyme Inhibitors: Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.TetrazolesCyclic AMP: An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH.Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Rabbits: The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.Cannabinoid Receptor Antagonists: Compounds that inhibit or block the activity of CANNABINOID RECEPTORS.Brain: The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.Receptors, Neurokinin-1: A class of cell surface receptors for TACHYKININS with a preference for SUBSTANCE P. Neurokinin-1 (NK-1) receptors have been cloned and are members of the G protein coupled receptor superfamily. They are found on many cell types including central and peripheral neurons, smooth muscle cells, acinar cells, endothelial cells, fibroblasts, and immune cells.Muscle Contraction: A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.Prostaglandin Antagonists: Compounds that inhibit the action of prostaglandins.Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.Receptors, Dopamine D2: A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES.Dioxanes: 1,4-Diethylene dioxides. Industrial solvents. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), dioxane itself may "reasonably be anticipated to be a carcinogen." (Merck Index, 11th ed)Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Adenosine: A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.Mineralocorticoid Receptor Antagonists: Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Injections, Intraventricular: Injections into the cerebral ventricles.Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.Receptors, Opioid: Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known.Muscle, Smooth: Unstriated and unstriped muscle, one of the muscles of the internal organs, blood vessels, hair follicles, etc. Contractile elements are elongated, usually spindle-shaped cells with centrally located nuclei. Smooth muscle fibers are bound together into sheets or bundles by reticular fibers and frequently elastic nets are also abundant. (From Stedman, 25th ed)GABA-B Receptor Antagonists: Drugs that bind to but do not activate GABA-B RECEPTORS thereby blocking the actions of endogenous or exogenous GABA-B RECEPTOR AGONISTS.Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.Receptor, Cannabinoid, CB1: A subclass of cannabinoid receptor found primarily on central and peripheral NEURONS where it may play a role modulating NEUROTRANSMITTER release.Receptors, Vasopressin: Specific molecular sites or proteins on or in cells to which VASOPRESSINS bind or interact in order to modify the function of the cells. Two types of vasopressin receptor exist, the V1 receptor in the vascular smooth muscle and the V2 receptor in the kidneys. The V1 receptor can be subdivided into V1a and V1b (formerly V3) receptors.Blood Pressure: PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.beta Catenin: A multi-functional catenin that participates in CELL ADHESION and nuclear signaling. Beta catenin binds CADHERINS and helps link their cytoplasmic tails to the ACTIN in the CYTOSKELETON via ALPHA CATENIN. It also serves as a transcriptional co-activator and downstream component of WNT PROTEIN-mediated SIGNAL TRANSDUCTION PATHWAYS.Receptors, G-Protein-Coupled: The largest family of cell surface receptors involved in SIGNAL TRANSDUCTION. They share a common structure and signal through HETEROTRIMERIC G-PROTEINS.Tumor Necrosis Factor-alpha: Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)Receptors, Opioid, mu: A class of opioid receptors recognized by its pharmacological profile. Mu opioid receptors bind, in decreasing order of affinity, endorphins, dynorphins, met-enkephalin, and leu-enkephalin. They have also been shown to be molecular receptors for morphine.BenzodiazepinonesEndothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)Receptor, Endothelin B: A subtype of endothelin receptor found predominantly in the KIDNEY. It may play a role in reducing systemic ENDOTHELIN levels.Receptors, Cholecystokinin: Cell surface proteins that bind cholecystokinin (CCK) with high affinity and trigger intracellular changes influencing the behavior of cells. Cholecystokinin receptors are activated by GASTRIN as well as by CCK-4; CCK-8; and CCK-33. Activation of these receptors evokes secretion of AMYLASE by pancreatic acinar cells, acid and PEPSIN by stomach mucosal cells, and contraction of the PYLORUS and GALLBLADDER. The role of the widespread CCK receptors in the central nervous system is not well understood.N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Models, Molecular: Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.Cholinergic Antagonists: Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists.Patch-Clamp Techniques: An electrophysiologic technique for studying cells, cell membranes, and occasionally isolated organelles. All patch-clamp methods rely on a very high-resistance seal between a micropipette and a membrane; the seal is usually attained by gentle suction. The four most common variants include on-cell patch, inside-out patch, outside-out patch, and whole-cell clamp. Patch-clamp methods are commonly used to voltage clamp, that is control the voltage across the membrane and measure current flow, but current-clamp methods, in which the current is controlled and the voltage is measured, are also used.Capsaicin: An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS.Receptors, Bradykinin: Cell surface receptors that bind BRADYKININ and related KININS with high affinity and trigger intracellular changes which influence the behavior of cells. The identified receptor types (B-1 and B-2, or BK-1 and BK-2) recognize endogenous KALLIDIN; t-kinins; and certain bradykinin fragments as well as bradykinin itself.Bicuculline: An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors.Receptors, GABA-A: Cell surface proteins which bind GAMMA-AMINOBUTYRIC ACID and contain an integral membrane chloride channel. Each receptor is assembled as a pentamer from a pool of at least 19 different possible subunits. The receptors belong to a superfamily that share a common CYSTEINE loop.Bradykinin: A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter.Receptors, Purinergic P1: A class of cell surface receptors that prefer ADENOSINE to other endogenous PURINES. Purinergic P1 receptors are widespread in the body including the cardiovascular, respiratory, immune, and nervous systems. There are at least two pharmacologically distinguishable types (A1 and A2, or Ri and Ra).2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.Gonadotropin-Releasing Hormone: A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.Beta Rhythm: Brain waves with frequency between 15-30 Hz seen on EEG during wakefulness and mental activity.Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.Receptors, Opioid, kappa: A class of opioid receptors recognized by its pharmacological profile. Kappa opioid receptors bind dynorphins with a higher affinity than endorphins which are themselves preferred to enkephalins.Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.Receptors, Neurokinin-2: A class of cell surface receptors for tachykinins that prefers neurokinin A; (NKA, substance K, neurokinin alpha, neuromedin L), neuropeptide K; (NPK); or neuropeptide gamma over other tachykinins. Neurokinin-2 (NK-2) receptors have been cloned and are similar to other G-protein coupled receptors.Histamine: An amine derived by enzymatic decarboxylation of HISTIDINE. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.Electrophysiology: The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.Bicyclo Compounds, Heterocyclic: A class of saturated compounds consisting of two rings only, having two or more atoms in common, containing at least one hetero atom, and that take the name of an open chain hydrocarbon containing the same total number of atoms. (From Riguady et al., Nomenclature of Organic Chemistry, 1979, p31)Benzimidazoles: Compounds with a BENZENE fused to IMIDAZOLES.Adrenergic beta-3 Receptor Antagonists: Drugs that bind to and block the activation of ADRENERGIC BETA-3 RECEPTORS.Adrenergic beta-1 Receptor Antagonists: Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS.Protein Subunits: Single chains of amino acids that are the units of multimeric PROTEINS. Multimeric proteins can be composed of identical or non-identical subunits. One or more monomeric subunits may compose a protomer which itself is a subunit structure of a larger assembly.Cell Membrane: The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.Receptors, Interleukin-1: Cell surface receptors that are specific for INTERLEUKIN-1. Included under this heading are signaling receptors, non-signaling receptors and accessory proteins required for receptor signaling. Signaling from interleukin-1 receptors occurs via interaction with SIGNAL TRANSDUCING ADAPTOR PROTEINS such as MYELOID DIFFERENTIATION FACTOR 88.QuinolinesAdrenergic alpha-Agonists: Drugs that selectively bind to and activate alpha adrenergic receptors.Naphthalenes: Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.Acetylcholine: A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system.Synaptic Transmission: The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES.Cell Line, Tumor: A cell line derived from cultured tumor cells.Receptors, Muscarinic: One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology.Cytokines: Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)QuinuclidinesAngiotensin II: An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.Rats, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding.Protein Conformation: The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).DNA Polymerase beta: A DNA repair enzyme that catalyzes DNA synthesis during base excision DNA repair. EC 2.7.7.7.
Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. (1/4656)
Impaired cardiac sympathetic activity can be evaluated by 123I-metaiodobenzylguanidine (MIBG) imaging. METHODS: We studied the significance of MIBG imaging for 24 patients (age 58+/-12 y) with dilated cardiomyopathy (DCM). We compared 12 patients (group A) treated with metoprolol (dose from 30-60 mg/d) with 12 patients treated with angiotensin-converting enzyme (ACE) inhibitors. Patients were studied before treatment, after 5 mo of treatment (only in group A) and after 1 y of treatment. Cardiac MIBG uptake was assessed as the heart-to-mediastinum activity ratio (H/M) and total defect score (TDS) from anterior planar and SPECT MIBG images, which were acquired in 4 h after tracer injection. New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF) calculated by echocardiography were also assessed. RESULTS: TDS decreased in both groups (in group A, from 30+/-7 through 23+/-9 to 18+/-10; P < 0.01, in group B, from 30+/-6 to 24+/-8; P < 0.01) and H/M was increased in both groups (in group A, from 1.87+/-0.31 through 2.03+/-0.28 to 2.14+/-0.29; P < 0.01, in group B, from 1.82+/-0.28 to 1.94+/-0.26; P < 0.05). But TDS and H/M were more improved in group A than in group B (P < 0.05). LVEF was significantly increased in only group A (from 38+/-6 through 43+/-8 to 49%+/-9%; P < 0.01). NYHA improved in both groups (in group A, from mean 2.5 through 2.1 to 1.8; P < 0.01, in group B, from mean 2.6 to 2.1; P < 0.05) but was more improved in group A than in group B (P < 0.05). CONCLUSION: Cardiac function, symptom and cardiac sympathetic activity evaluated by MIBG images improved after the beta-blocker therapy more than with the treatment that used ACE inhibitors. (+info)Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. (2/4656)
Norepinephrine (NE) reuptake function is impaired in heart failure and this may participate in myocyte hyperstimulation by the neurotransmitter. This alteration can be assessed by 123I-metaiodobenzylguanidine (MIBG) scintigraphy. METHODS: To determine whether the impairment of neuronal NE reuptake was reversible after metoprolol therapy, we studied 18 patients (43+/-7 y) with idiopathic dilated cardiomyopathy who were stabilized at least for 3 mo with captopril and diuretics. Patients underwent, before and after 6 mo of therapy with metoprolol, measurements of radionuclide left ventricular ejection fraction (LVEF), maximal oxygen consumption and plasma NE concentration. The cardiac adrenergic innervation function was scintigraphically assessed with MIBG uptake and release measurements on the planar images obtained 20 min and 4 h after tracer injection. To evaluate whether metoprolol had a direct interaction with cardiac MIBG uptake and release, six normal subjects were studied before and after a 1-mo metoprolol intake. RESULTS: In controls, neither cardiac MIBG uptake and release nor circulating NE concentration changed after the 1-mo metoprolol intake. Conversely, after a 6-mo therapy with metoprolol, patients showed increased cardiac MIBG uptake (129%+/-10% versus 138%+/-17%; P = 0.009), unchanged cardiac MIBG release and decreased plasma NE concentration (0.930+/-412 versus 0.721+/-0.370 ng/mL; P = 0.02). In parallel, patients showed improved New York Heart Association class (2.44+/-0.51 versus 2.05+/-0.23; P = 0.004) and increased LVEF (20%+/-8% versus 27%+/-8%; P = 0.0005), whereas maximal oxygen uptake remained unchanged. CONCLUSION: Thus, a parallel improvement of myocardial NE reuptake and of hemodynamics was observed after a 6-mo metoprolol therapy, suggesting that such agents may be beneficial in heart failure by directly protecting the myocardium against excessive NE stimulation. (+info)QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion. (3/4656)
OBJECTIVE: To compare QT dispersion in patients with impaired left ventricular systolic function and in matched control patients with normal left ventricular systolic function. DESIGN: A retrospective, case-control study with controls matched 4:1 for age, sex, previous myocardial infarction, and diuretic and beta blocker treatment. SETTING: A regional cardiology centre and a university teaching hospital. PATIENTS: 25 patients with impaired left ventricular systolic function and 100 patients with normal left ventricular systolic function. MAIN OUTCOME MEASURES: QT and QTc dispersion measured by three methods: the difference between maximum and minimum QT and QTc intervals, the standard deviation of QT and QTc intervals, and the "lead adjusted" QT and QTc dispersion. RESULTS: All measures of QT/QTc dispersion were closely interrelated (r values 0.86 to 0.99; all p < 0.001). All measures of QT and QTc dispersion were significantly increased in the patients with impaired left ventricular systolic function v controls (p < 0.001): 71.9 (6.5) (mean (SEM)) v 46.9 (1.7) ms for QT dispersion, and 83.6 (7.6) v 54.3 (2.1) ms(-1-2) for QTc dispersion. All six dispersion parameters were reduced in patients taking beta blockers (p < 0.05), regardless of whether left ventricular function was normal or impaired-by 9.4 (4.6) ms for QT dispersion (p < 0.05) and by 13.8 (6. 5) ms(-1-2) for QTc dispersion (p = 0.01). CONCLUSIONS: QT and QTc dispersion are increased in patients with systolic heart failure in comparison with matched controls, regardless of the method of measurement and independently of possible confounding factors. beta Blockers are associated with a reduction in both QT and QTc dispersion, raising the possibility that a reduction in dispersion of ventricular repolarisation may be an important antiarrhythmic mechanism of beta blockade. (+info)AV reentrant and idiopathic ventricular double tachycardias: complicated interactions between two tachycardias. (4/4656)
An electrophysiological study was performed in a 61 year old man with Wolff- Parkinson-White (WPW) syndrome. At baseline, neither ventricular nor supraventricular tachycardias could be induced. During isoprenaline infusion, ventricular tachycardia originating from the right ventricular outflow tract (RVOT) with a cycle length of 280 ms was induced and subsequently atrioventricular reentrant tachycardia (AVRT) with a cycle length of 300 ms using an accessory pathway in the left free wall appeared. During these tachycardias, AVRT was entrained by ventricular tachycardia. The earliest ventricular activation site during the ventricular tachycardia was determined to be the RVOT site and a radiofrequency current at 30 W successfully ablated the ventricular tachycardia at this site. The left free wall accessory pathway was also successfully ablated during right ventricular pacing. The coexistence of WPW syndrome and cathecolamine sensitive ventricular tachycardia originating from the RVOT has rarely been reported. Furthermore, the tachycardias were triggered by previous tachycardias. (+info)Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. (5/4656)
The long-acting beta2 sympathomimetics salmeterol and formoterol have been presumed to exert their prolonged action either by binding to an accessory binding site ("exo-site") near the beta2 adrenoceptor or by their high affinity for beta2 adrenoceptors and correspondingly slow dissociation. Whereas most studies with salmeterol had been done in intact tissues, which have slow diffusion and compartmentation of drugs in lipophilic phases, that restrict drug access to the receptor biophase, we used purified receptor membranes from rat lung and disaggregated calf tracheal myocytes as model systems. Binding experiments were designed to measure the slow dissociation of agonists by means of delayed association of (-)-[125I]iodopindolol. Rat lung membranes were pretreated with high concentrations of agonists (salmeterol, formoterol, isoprenaline) before dissociation was induced by 50-fold dilution. Half-times of association of (-)-[125I]iodopindolol remained unchanged compared with untreated controls, indicating that dissociation of agonists occurred in less than 2 min. Adenylyl cyclase experiments were designed to determine the on and off kinetics of agonists to beta2 adrenoceptors by measuring the rate of receptor-induced cyclic AMP (cAMP) formation. Experiments were performed in tracheal membranes characterized by high Vmax values of cAMP formation. Adenylyl cyclase activation occurred simultaneously with the addition of the agonist, continued linearly with time for 60 min, and ceased immediately after the antagonist was added. Similarly, when receptor membranes were preincubated in a small volume with high salmeterol concentrations, there was a linear increase in cAMP formation, which was immediately interrupted by a 100-fold dilution of the reaction mixture. This militates against the exo-site hypothesis. On the other hand, dissociation by dilution was much less when membranes were preincubated with a large volume of salmeterol at the same concentration, indicating that physicochemical effects, and not exo-site binding, underlie its prolonged mode of action. (+info)Mechanisms of prostaglandin E2 release by intact cells expressing cyclooxygenase-2: evidence for a 'two-component' model. (6/4656)
Prostaglandin (PG) release in cells expressing constitutive cyclooxygenase-1 is known to be regulated by liberation of arachidonic acid by phospholipase A2 followed by metabolism by cyclooxygenase. However, the relative contribution of phospholipase A2 to the release of PGs in cells expressing cyclooxygenase-2 is not clear. We addressed this question by using radioimmunoassay to measure PGE2 release by human cells (A549) induced to express cyclooxygenase-2 (measured by Western blot analysis) by interleukin-1beta. Cells were either unstimulated or stimulated with agents known to activate phospholipase A2 (bradykinin, Des-Arg10-kallidin, or the calcium ionophore A23187) or treated with exogenous arachidonic acid. When cells were treated to express cyclooxygenase-2, the levels of PGE2 released over 15 min were undetectable; however, in the same cells stimulated with bradykinin, A23187, or arachidonic acid, large amounts of prostanoid were produced. Using selective inhibitors/antagonists, we found that the effects of bradykinin were mediated by B2 receptor activation and that prostanoid release was due to cyclooxygenase-2, and not cyclooxygenase-1, activity. In addition, we show that the release of PGE2 stimulated by either bradykinin, A23187, or arachidonic acid was inhibited by the phospholipase A2 inhibitor arachidonate trifluoromethyl ketone. Hence, we have demonstrated that PGE2 is released by two components: induction of cyclooxygenase-2 and supply of substrate, probably via activation of phospholipase A2. This is illustrated in A549 cells by a clear synergy between the cytokine interleukin-1beta and the kinin bradykinin. (+info)Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. (7/4656)
The purpose of the present study was to confirm the presence of beta3-adrenoceptor subtype in the relaxation of human urinary bladder detrusor tissue by reverse transcription-polymerase chain reaction (PCR); direct sequencing of the PCR product, in situ hybridization; and isometric contraction. Using reverse transcription-PCR, the mRNAs of three receptor subtypes (beta1, beta2, and beta3) were expressed in the human urinary bladder detrusor tissue. Direct sequencing of the PCR product of the above beta3-adrenoceptor revealed no mutation in the amplified regions. In situ hybridization with digoxygenin-labeled oligonucleotide probe revealed the presence of the mRNA of beta3-adrenoceptor subtype in the smooth muscle of the urinary bladder. The relaxant effects of isoproterenol (a nonselective beta-adrenoceptor agonist); ZD7114, BRL37344, and CGP12177A (putative selective beta3-adrenoceptor agonists); and SR59230A (a putative selective beta3-adrenoceptor antagonist) were tested using an isometric contraction technique. Isoproterenol in either the presence or absence of both atenolol (a beta1-adrenoceptor-selective antagonist) and butoxamine (a beta2-adrenoceptor-selective antagonist) revealed a relaxant effect on the carbachol-induced contraction of the human urinary bladder detrusor. Both BRL37344 and CGP12177A also revealed relaxant effects on the human urinary bladder detrusor, but ZD7114 did not elicit any relaxation. These results suggest that beta3-adrenoceptor may have some role in urine storage in the human urinary bladder. (+info)Adrenoreceptors of the guinea-pig urinary bladder. (8/4656)
1 Adrenaline, noradrenaline and isoprenaline (5 mug/ml) did not affect the resting tone of the isolated urinary bladder of the guinea-pig. 2 The catecholamines (1-2 mug/ml) inhibited neuronally evoked contractions at various stimulation frequencies; the inhibition was maximum at 2 Hz and minimum at 50 Hz. Isoprenaline produced maximum inhibition. 3 Propranolol (0.5 mug/ml) completely blocked the catecholamine-induced inhibition at all the frequencies employed. The concentration-response curves of isoprenaline at 2, 10 and 50 Hz were characteristically shifted by propranolol (50 ng/ml). Phenoxybenzamine (0.2 mug/ml) was totally ineffective. 4 In some experiments adrenaline significantly raised the tone of the bladder exposed to propranolol; this effect could be blocked by phenoxybenzamine. 5 Acetylcholine-induced bladder contractions were inhibited by adrenaline (2 mug/ml); the inhibition was completely blocked by propranolol (0.5 mug/ml). 6 The results indicate the presence of an inhibitory beta-adrenoceptor and suggest the possibility of an excitatory alpha-adrenoceptor in guinea-pig urinary bladder. (+info)
Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary...
ETIS - The effect of heart rate on brachial and central blood pressure in longterm beta-blocker therapy
Abstract 2841: Beta-Blocker Therapy Abolishes Postsystolic Shortening in Patients with Nonischemic Dilated Cardiomyopathy |...
Research suggests beta-blockers may prevent osteoporosis fractures
2019 MIPS Measure #442: Persistence of Beta-Blocker Treatment After a Heart Attack | MDinteractive
Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation | JACC: Heart Failure
Gestational Outcomes of Beta Blocker Therapy as a Treatment of Palpitations | OMICS International
BestBets: Are prophylactic beta-blockers of benefit in reducing the incidence of AF following coronary bypass surgery?
"Beta-blocker initiation and adherence after hospitalization for acute " by Vittorio Maio, PharmD, MS, MSPH, Massimiliano...
Ivabradine - DrugBank
Beta-Blockers Don't Block Heart Attacks or Stroke | YourMedicalSource
Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? | Annals of the Rheumatic...
Beta Blockers - Symptoms, Treatments and Resources for Beta Blockers
Beta-blockers lower blood pressure when given as a second drug | Cochrane
DECREASE III: Beta-blocker use to lower operative mortality in high-risk vascular surgery - Vascular News
Notes from Dr. RW: Benefits of long term beta blocker use after CABG
Genetic Determinants of Response to Beta Blockade - Full Text View - ClinicalTrials.gov
Beta-blockers | Reston Hospital Center
Beta-blockers | Memorial Hospital
Beta-blockers | Portsmouth Regional Hospital
Beta-blockers | Oak Hill Hospital | Brooksville, FL
Beta-blockers | Wesley Medical Center
Beta-Blockers for Hypertension - SA Birth Classes
Beta-blockers are history - Addendum… - Ron's Rants…
Questioning Beta-Blockers in Surgery
Questions Continue About Using Beta Blockers Before Surgery - Drugs.com MedNews
Beta-Adrenergic Blocking Agents, Also Called Beta-Blockers | HowStuffWorks
Nebivolol- Another Excellent Beta Blocker For Hypertension
beta blocker - definition and meaning
Beta blockers - Your.MD
Beta-Blockers | Blausen Medical
Beta-Blockers - ONA
Not all beta-blockers are equal in the management of Long QT Syndrome types 1 and 2 : higher recurrence of events under...
Adrenergic beta-antagonists | definition of Adrenergic beta-antagonists by Medical dictionary
Cardiovascular Diseases
Brefonalol... is a beta-adrenergic antagonist. Halabi, A; Endell, W; Halabi, I; Kirch, W (1990). "Hemodynamic effects of ...
... is a beta-adrenergic antagonist. Nakayama, K; Oshima, T; Koike, H (1981). "Assessment of beta-blockade and the non- ... a beta-adrenergic blocking agent, on atrioventricular conduction in anesthetized dogs". Archives Internationales de ...
Beta blocker Adrenergic antagonists Katzung, Bertram; Masters, Susan (2013). Basic and Clinical Pharmacology. Lange. ISBN 978-0 ... Non-selective α-adrenergic receptor antagonists include: Phenoxybenzamine Phentolamine Tolazoline Trazodon Selective α1- ... are a class of pharmacological agents that act as antagonists on α-adrenergic receptors (α-adrenoceptors). Historically, alpha- ... adrenergic receptor antagonists include: Alfuzosin Doxazosin Prazosin (inverse agonist) Tamsulosin Terazosin Silodosin ...
... is a beta adrenergic antagonist. It is the (S)-enantiomer of moprolol. Gianesello, V; Brenn, E; Figini, G; ... Gazzaniga, A (1989). "Determination by coupled high-performance liquid chromatography-gas chromatography of the beta-blocker ...
... is a beta adrenergic receptor antagonist. Stache, U; Fritsch, W; Fehlhaber, HW (1987). "Synthesis of the highly ... cardioselective beta-sympatholytic pacrinolol". Arzneimittel-Forschung. 37 (11): 1217-21. PMID 2894210. ...
... is an antiarrhythmic beta adrenergic antagonist. Koytchev, R; Alken, RG; Mayer, O; Smith, I; Greenwood, M (1996). " ...
... is a beta adrenergic receptor antagonist. Lombardi, F; Terranova, P (2006). "Pharmacological treatment of atrial ...
... is a beta adrenergic receptor antagonist. Mahé, N; Do, B; Nicolaï, B; Rietveld, IB; Barrio, M; Tamarit, JL; Céolin, ...
... is a beta adrenergic receptor antagonist. Allen, JD; Shanks, RG (1974). "Effects of tiprenolol, practolol and ...
... is a beta adrenergic receptor antagonist. Mostaghim, R; Maddox, YT; Ramwell, PW (1986). "Endothelial potentiation ... of relaxation response to beta adrenoceptor blocking agents". The Journal of Pharmacology and Experimental Therapeutics. 239 (3 ...
... is a beta adrenergic receptor antagonist. Hugues, FC; Julien, D; Bors, V; Mougeot, G; Marche, J (1980). "Determination ... in man of the beta blocking properties and the pharmacological half of pargolol (Author's transl)". Therapie. 35 (4): 475-81. ...
Timolol is a non-selective beta-adrenergic antagonist. Common adverse effects include temporarily blurred vision, cloudy vision ...
... seems to have beta-adrenergic antagonist properties. The Plant List "BSBI List 2007". Botanical Society of ...
... is a beta adrenergic antagonist. Cardioselective b1-adrenergic blocker. Klausner, MA; Irwin, C; Mullane, JF; Shand, ...
Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC (May 1964). "A new adrenergic beta receptor antagonist". Lancet. 1 ( ... The first member was verapamil, a derivative of papaverine that was initially thought to be a beta blocker and used for angina ... The British physician James W. Black developed beta blockers in the early 1960s; these were initially used for angina, but ... February 1996). "Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy". J. Med. Chem ...
... is a beta-adrenergic antagonist. Cheymol, G; Jaillon, P; Lecoq, B; Lecoq, V; Cheymol, A; Krumenacker, M (1987). " ... "Cardiovascular beta-adrenergic blocking effects of bornaprolol in humans: Relation to dose and plasma concentration". Journal ...
... is a beta-adrenergic antagonist. Haddad, S; Poulin, P; Funk, C (2010). "Extrapolating in vitro metabolic ...
J. W. Black; A. F. Crowther; R. G. Shanks; A. C. Dornhorst (1964). "A new adrenergic beta-receptor antagonist". The Lancet. 283 ... as either alpha or beta adrenergic blocking drugs." Dichloroisoprenaline was the first beta blocker; it retains some intrinsic ... that both are beta type receptors. … It is suggested that this terminology be extended to the realm of adrenergic blocking ... he called beta adrenotropic receptor (now β-adrenoceptor or β-adrenergic receptor). ″This concept of two fundamental types of ...
Adverse experience with cimetidine and safety of beta-adrenergic antagonists". Arch Intern Med. 145 (12): 2197-200. doi:10.1001 ... Previously, beta blockers have been assumed as risk factor for the acquisition of contrast medium-induced adverse reactions/ ... Due to recent investigations it became clear that beta blockers do not have the ability to increase the frequency of adverse ... Boehm I, Morelli J, Nairz K, Silva Hasembank Keller P, Heverhagen JT (2016). "Beta blockers and intravenous roentgen contrast ...
... is a beta-adrenergic receptor antagonist. Conti, P; Dallanoce, C; De Amici, M; De Micheli, C; Klotz, KN (1998). " ... of new delta 2-isoxazoline derivatives and their pharmacological characterization as beta-adrenergic receptor antagonists". ...
... is a beta adrenergic receptor antagonist. Curtis-Prior, PB; Gadd, AL (1990). "Beta-adrenoceptor antagonists and human ...
... is a beta adrenergic receptor antagonist. Lennernäs, H; Regårdh, CG (1993). "Dose-dependent intestinal absorption and ... significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat". Pharmaceutical Research. 10 (5): 727- ...
... is a beta adrenergic receptor antagonist. The methyl group on a sulfoxide is sufficiently acidic to substitute for ... "Studies on the mechanism of the acute antihypertensive and vasodilator actions of several beta-adrenoceptor antagonists". J. ...
... is a beta adrenergic receptor antagonist. Singh, KP (1983). "Influence of beta-adrenoceptor antagonists on ...
... is a beta adrenergic receptor antagonist. Mannucci, C; Caviglioli, G; Perico, A; Triolo, A (1992). "High-performance ...
... increase beta adrenergic receptors while decreasing alpha adrenergic receptors- which results in increased levels of ... GnRH antagonists (e.g., cetrorelix). *Progestogens (incl., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone ... D2 receptor antagonists (prolactin releasers) (e.g., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, ... nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to ...
Adrenergic Beta-antagonists | Encyclopedia.comBeta Blockers Definition Beta blockers are medicines that affect the bodys response to certain nerve impulses. This, in turn, ... Beta blockers. Definition. Beta blockers, also known as beta antagonists, are a class of drugs that were first developed for ... Home Literature and the Arts Art and Architecture Art: General Adrenergic beta-antagonists ... Beta blockers, also known as beta antagonists, are a class of drugs that were first developed for the treatment of certain ...
Comparison of Adrenergic Beta-receptor Antagonists in Angina Pectoris | The BMJComparison of Adrenergic Beta-receptor Antagonists in Angina Pectoris Br Med J 1973; 1 :138 ... Comparison of Adrenergic Beta-receptor Antagonists in Angina Pectoris. Br Med J 1973; 1 doi: https://doi.org/10.1136/bmj.1.5846 ... suggests that metabolic breakdown products are probably of therapeutic importance only in so far as they antagonize beta- ...
Adrenergic beta Antagonists - Medical Dictionary online-medical-dictionary.orgAdrenergic beta Antagonists. Drugs that bind to but do not activate beta-Adrenergic Receptors thereby blocking the actions of ... beta-Adrenergic Agonists. Adrenergic beta-antagonists are used for treatment of Hypertension, Cardiac Arrhythmias, Angina ...
Adrenergic beta-Antagonists | CTD... beta-Adrenergic , Antagonists, beta-Adrenoceptor , beta Adrenergic Antagonists , beta-Adrenergic Antagonists , beta Adrenergic ... Adrenergic beta-Antagonists Equivalent Terms Adrenergic beta Antagonists , Adrenergic beta-Blockers , Adrenergic beta Receptor ... beta-Adrenoceptor Antagonists , beta-Antagonists, Adrenergic , beta Blockers, Adrenergic , beta-Blockers, Adrenergic , beta- ... Adrenergic Agents ← Adrenergic Antagonists ← Adrenergic beta-Antagonists 2.. Chemicals ← Chemical Actions and Uses ← ...
A Beta-2 adrenergic antagonist (β2-adrenoceptor antagonist) is an adrenergic antagonist which blocks the beta-2 adrenergic ... ICI-118,551 Butaxamine Propranolol Betablocker Beta-2 adrenergic receptor Beta2-adrenergic agonist Bilski, AJ; Halliday, SE; ... Fitzgerald, JD; Wale, JL (1983). "The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551)". J Cardiovasc ... an antagonist for β2 and for β1 or β3 adrenoceptors) like the non-selective betablocker Propranolol. ...
A Beta-3 adrenergic antagonist (β3-adrenoceptor antagonist) is an adrenergic antagonist which blocks the Beta-3 adrenergic ... "Potent and selective human beta(3)-adrenergic receptor antagonists". The Journal of Pharmacology and Experimental Therapeutics ... SR 59230A Carvedilol Betablocker Beta-3 adrenergic receptor Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, ... an antagonist for β3 and for β1 or β2 adrenoceptors) like the non-selective betablocker Carvedilol. ...
Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000 ( ...... beta,2-adrenergic,receptor,antagonists,using,CypHer5E,and,IN,Cell,Analyzer,1000,biological,advanced biology technology,biology ... has been used to obtain dose-response and rank-order potency data for both agonist and antagonist treatment of β2-adrenergic ... Introduction CypHer ™ 5 a pH sensitive dye has shown utility in β2-adrenergic receptor agonist screening (1). CypHer5 ... Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000 ...
Histamine H2 Antagonists. *Alpha/Beta Adrenergic Agonists. *Local Anesthetics, Amides. *Show All ... Alpha/Beta Adrenergic Agonists. Class Summary. These agents may be used to treat nasal congestion. ... Histamine H2 Antagonists. Class Summary. H2 blockers are reversible competitive blockers of histamine at H2 receptors, ... Histamine 2 (H2)-receptor antagonists should be administered preoperatively to prevent increase in gastric secretion during the ...
AID 1135146 - Antagonist activity at guinea pig atrial beta adrenergic receptor assessed as isometric contractions at 5 x 10'-5...Antagonist activity at guinea pig atrial beta adrenergic receptor assessed as isometric contractions at 5 x 10-5 M by force ...
Binding of adrenergic beta-receptor antagonists to human serum albumin. - Semantic ScholarBinding of adrenergic beta-receptor antagonists to human serum albumin. by C Appelgren et al. ... Binding of adrenergic beta-receptor antagonists to human serum albumin.. @article{Appelgren1974BindingOA, title={Binding of ... adrenergic beta-receptor antagonists to human serum albumin.}, author={C Appelgren and Karl O. Borg and Rolf Elofsson and Karl ... The relationship between beta-adrenoceptors and adrenergic responsiveness in trout (Oncorhynchus mykiss) and eel (Anguilla ...
Effects of alpha, beta 1, and beta 2 adrenergic antagonists on...... and beta 2 adrenergic antagonists on the Na and K concentrations of sympathetic-nerve stimulated rat saliva.: Selective alpha ... Effects of alpha, beta 1, and beta 2 adrenergic antagonists on the Na and K concentrations of sympathetic-nerve stimulated rat ... Selective alpha and beta 1 and beta 2 adrenergic antagonists were used with electrical stimulation of the sympathetic ... innervation to parotid and submandibular glands of rats in order to delineate the role of the beta 1 and beta 2 adrenoceptors ...
What is Adrenergic beta-antagonists? Meaning of Adrenergic beta-antagonists medical term. What does Adrenergic beta-antagonists ... Looking for online definition of Adrenergic beta-antagonists in the Medical Dictionary? Adrenergic beta-antagonists explanation ... beta blocker. (redirected from Adrenergic beta-antagonists). Also found in: Dictionary, Thesaurus, Encyclopedia. beta blocker. ... Adrenergic beta-antagonists , definition of Adrenergic beta-antagonists by Medical dictionary https://medical-dictionary. ...
This group of antagonists are generally used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, ... Natural or synthetic beta adrenergic antagonists selectively or non-selectively blocking or diminishing physiologic beta- ... Adrenergic beta-Antagonists. Known as: beta-adrenergic blockers, Beta-Adrenergic Blocking Agent, Adrenergic beta-Receptor ... Natural or synthetic beta adrenergic antagonists selectively or non-selectively blocking or diminishing physiologic beta- ...
Prostaglandin I2
-
Adrenergic beta-Antagonists, ATC:C07AB09For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention ...
Adrenergic beta-1 Receptor Antagonists. Heres what weve found for you. Adrenergic beta-1 Receptor Antagonists Adrenergic beta ... BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists A cardioselective beta-1-adrenergic antagonist ... SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists A cardioselective beta-adrenergic ... approved Adrenergic beta-1 Receptor Antagonists BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING ...
Adrenergic beta-1 Receptor Antagonists Drugs on Prescription | RX24DrugsSave money on Adrenergic beta-1 Receptor Antagonists with free prescription coupons from RX24Drugs. We support biggest US ...
Nadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol ... Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little ... Although cardiac failure rarely occurs in properly selected patients, patients being treated with beta-adrenergic blocking ... Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac ...
HomeThe role of beta-adrenergic receptor antagonists in the p. The role of beta-adrenergic receptor antagonists in the p. By ...
Find out information about beta-adrenergic antagonist. 1. any muscle that opposes the action of another 2. a drug that ... counteracts the effects of another drug A molecule that bears sufficient structural... Explanation of beta-adrenergic ... antagonist. (redirected from beta-adrenergic antagonist). Also found in: Dictionary, Thesaurus, Medical, Legal. antagonist. 1. ... Beta-adrenergic antagonist , Article about beta-adrenergic antagonist by The Free Dictionary https://encyclopedia2. ...
Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: and the winner is... - PubMed - NCBIAdrenergic beta-Antagonists/therapeutic use. *Endoscopy, Gastrointestinal/methods*. *Esophageal and Gastric Varices/prevention ...
Adrenergic beta-Antagonists. LinkOut - more resources. Full Text Sources. *Atypon - PDF. *Atypon ... and there was no interaction between the use or nonuse of beta-blockade and the predictive power of exercise capacity. Each 1- ...
Adrenergic Agents. Adrenergic beta-Antagonists. Adrenergic Antagonists. Neurotransmitter Agents. Molecular Mechanisms of ... Experimental: Adrenergic Blockade Propranolol and Clonidine. Drug: IV Propranolol and Per Tube Clonidine 1 mg IV q6h ... DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury. This study has been ... Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH ...
Adrenergic beta-Antagonists. Adrenergic Antagonists. Adrenergic Agents. Neurotransmitter Agents. Molecular Mechanisms of ... beta(2)-Adrenergic receptor and adenylate cyclase gene polymorphisms affect sickle red cell adhesion. Br J Haematol. 2008 Apr; ...
Adrenergic beta-Antagonists. Adrenergic Antagonists. Adrenergic Agents. Neurotransmitter Agents. Molecular Mechanisms of ... Previous adverse reaction to, or non-compliance with a beta-blocker.. *Current use of medication that may involve potentially ... occurred at any time in life if induced by a beta-blocker, or c) are currently being treated, regardless of the date of last ... dangerous interactions with propranolol, including, other beta-blockers, antiarrhythmics, calcium channel blockers, and potent ...
Adrenergic beta-Antagonists. Adrenergic Antagonists. Adrenergic Agents. Neurotransmitter Agents. Vasodilator Agents. Adrenergic ...
- A Beta-2 adrenergic antagonist (β2-adrenoceptor antagonist) is an adrenergic antagonist which blocks the beta-2 adrenergic receptors of cells, with either high specificity (an antagonist which is selective for β2 adrenoceptors) like Butaxamine and ICI-118,551, or non-specifically (an antagonist for β2 and for β1 or β3 adrenoceptors) like the non-selective betablocker Propranolol. (wikipedia.org)
- Synonyms : 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol, 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide, 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide, Atenololum Status : approved Antihypertensive Agents BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. (pharmakb.com)
- Nadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. (pharmacycode.com)
- Individual sensitivity to beta-blockade may be significantly reduced in those patients who have tolerated therapeutic doses of up to 4 g of propranolol daily and in patients who have sustained deliberate overdoses of both practolol and propranolol without serious adverse effects. (medscape.com)
- This reduction in QTc derived entirely from a decrease in the QTc among patients with a baseline abnormal QTc, in whom the shortening in the QTc was greater with propranolol than with either nadolol or metoprolol (p=0.04) since the change in QTc was comparable in all three beta blocker groups with a normal or borderline baseline QTc (p=0.8). (acc.org)
- Propranolol was the first clinically useful beta adrenergic receptor antagonist . (wikidoc.org)
- Propranolol, a non-selective beta-adrenergic antagonist with good penetration of the blood-brain barrier, has not been investigated for this purpose. (frontiersin.org)
- Propranolol is a non-selective beta-adrenergic antagonist that has good penetration of the blood-brain barrier ( 21 ). (frontiersin.org)
- Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. (neurolex.org)
- A beta-adrenergic antagonist similar in action to propranolol. (drugbank.ca)
- Drugs that bind to but do not activate beta-Adrenergic Receptors thereby blocking the actions of beta-Adrenergic Agonists . (online-medical-dictionary.org)
- An agent that binds to but does not activate beta -adrenergic receptors thereby blocking the actions of endogenous or exogenous beta -adrenergic agonists. (ebi.ac.uk)
- The investigators were interested in albuterol because other beta-2 agonists as a class had improved strength and function of healthy and diseased muscle in animal studies and human trials. (lww.com)
- Beta adrenergic agonists 3. (studystack.com)
- How does inuslin, beta adrenergic agonists cause hypokalemia? (studystack.com)
- Thus, prospective studies in animals and patients at different stages of heart failure should lead to identify the best therapeutic window to use ß 3 -AR agonists and/or antagonists. (springer.com)
- We studied the relationship between alpha- and beta-adrenergic agonists and the activity of carbonic anhydrase I and II in erythrocyte, clinical and vessel studies. (scielo.br)
- We believe that adrenergic agonists may have a dual mechanism of action: the first one consists of a catecholamine action on its receptor with the formation of a stimulus-receptor complex. (scielo.br)
- Our previous work has shown that alpha- and beta-adrenergic agonists activated purified and red cell CA while adrenergic antagonists inhibited CA and reduced the activating effect of agonists on this enzyme (15,16). (scielo.br)
- In the present investigation we studied the relationship between alpha- and beta-adrenergic agonists and CA activity in vasoconstriction mechanism. (scielo.br)
- Recent studies have examined the effectiveness of alpha-2 adrenergic agonists for controlling delirium and agitation. (frontiersin.org)
- Despite this early evidence supporting chronic use of beta blockers in asthma, there is concern in 2 major regards:their potential to cause acute airway narrowing (irrespective of longterm benefit) and the possibility that they could block the reliever action of beta agonists. (bioportfolio.com)
- A Beta-3 adrenergic antagonist (β3-adrenoceptor antagonist) is an adrenergic antagonist which blocks the Beta-3 adrenergic receptors of cells, with either high specificity (an antagonist which is selective for β3 adrenoceptors) like L-748,328, L-748,337 and SR 59,230A or non-specifically (an antagonist for β3 and for β1 or β2 adrenoceptors) like the non-selective betablocker Carvedilol. (wikipedia.org)
- CypHer5E, consequently, can be used to screen for novel antagonists of known receptors and for potential ligands of non-G-protein coupled receptors (5) and orphan receptors. (bio-medicine.org)
- The H2 antagonists are highly selective, they do not affect the H1 receptors, and they are not anticholinergic agents. (medscape.com)
- Adrenergic beta-1 Receptor Antagonists Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (pharmakb.com)
- Betaxolol selectively blocks catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle. (pharmakb.com)
- Beta-adrenergic antagonists , or beta-blockers, also might reduce stress-hormone-induced memory consolidation and fear conditioning by blocking postsynaptic norepinephrine receptors and impairing emotional memory, he said. (thefreedictionary.com)
- Inhibit or reverse the actions of the parasympathetic nervous system and bind with cholinergic receptors and prevent binding of acetylcholine (they are antagonists). (studystack.com)
- Beta blockers block the action of endogenous catecholamines ( epinephrine (adrenaline) and norepinephrine (noradrenaline) in particular), on β- adrenergic receptors , part of the sympathetic nervous system which mediates the " fight or flight " response. (wikidoc.org)
- β 1 -Adrenergic receptors are located mainly in the heart and in the kidneys. (wikidoc.org)
- Some beta blockers (e.g. labetalol and carvedilol ) exhibit mixed antagonism of both β- and α 1 -adrenergic receptors, which provides additional arteriolar vasodilating action. (wikidoc.org)
- By this second component of the mechanism, the same stimulus directly acts on the carbonic anhydrase I isozyme (that might be functionally coupled with adrenergic receptors), so that its activation ensures an adequate pH for stimulus-receptor coupling for signal transduction into the cell, resulting in vasoconstriction. (scielo.br)
- Important factors in the response of any cell or organ to sympathomimetic amines are the density and proportion of alpha- and beta-adrenergic receptors (3,4). (scielo.br)
- Studies on DNA cloning have demonstrated the existence of at least nine types of adrenergic receptors (5). (scielo.br)
- The norepinephrine provided by the LC acts at the medial septal area (MSA) and the medial preoptic area (MPOA) to activate waking-active neurons ( via alpha-1 adrenergic receptors) and inhibit sleep-active neurons ( via alpha-2 adrenergic receptors). (frontiersin.org)
- There are also beta-1, beta-2, and beta-3 adrenergic receptors in the MSA and MPOA ( 4 ). (frontiersin.org)
- It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. (neurolex.org)
- By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. (neurolex.org)
- Beta blockers are medicines that affect the body's response to certain nerve impulses. (encyclopedia.com)
- The main use of beta blockers is to treat high blood pressure . (encyclopedia.com)
- Beta blockers, also known as beta-adrenergic blockers, are available only with a physician's prescription. (encyclopedia.com)
- Timolol and certain other beta blockers are also sold in eye drop form for treating glaucoma. (encyclopedia.com)
- Eye drops that contain beta blockers include betaxolol (Betoptic), cartelol (Ocupress), and timolol (Timoptic). (encyclopedia.com)
- Some conditions may get worse when patients stop taking beta blockers abruptly. (encyclopedia.com)
- Seeing a physician regularly while taking beta blockers is important. (encyclopedia.com)
- Beta blockers will not cure high blood pressure, but will help control the condition. (encyclopedia.com)
- Anyone taking beta blockers for high blood pressure should not take any other prescription or over-the-counter medicine without first checking with his or her physician. (encyclopedia.com)
- Anyone who is taking beta blockers should be sure to tell the health care professional in charge before having any surgical or dental procedures or receiving emergency treatment. (encyclopedia.com)
- Some beta blockers may change the results of certain medical tests. (encyclopedia.com)
- Some people feel drowsy, dizzy, or lightheaded when taking beta blockers. (encyclopedia.com)
- Beta blockers may increase sensitivity to cold, especially in older people or people who have poor circulation. (encyclopedia.com)
- Beta-adrenergic antagonists , more commonly known as beta blockers, are identified easily by the name ending olol. (thefreedictionary.com)
- Despite the importance of beta-blockers for secondary prevention after acute myocardial infarction (AMI), several studies have suggested that they are substantially underutilized, particularly in older patients. (nih.gov)
- To describe the contemporary national pattern of beta-blocker prescription at hospital discharge among patients aged 65 years or older with an AMI, to identify the most important predictors of the prescribed use of beta-blockers at discharge, and to determine the independent association between beta-blockers at discharge and mortality in clinical practice. (nih.gov)
- Among the 45308 patients without contraindications to beta-blockers, 22665 (50.0%) had a beta-blocker as a discharge medication. (nih.gov)
- After adjusting for potential confounders, beta-blockers were associated with a 14% lower risk of mortality at 1 year after discharge. (nih.gov)
- Geographic factors and physician specialty are independently associated with the decision to use beta-blockers. (nih.gov)
- Elderly patients who are prescribed beta-blockers at discharge have a better survival rate, consistent with the findings of randomized controlled trials of younger and lower-risk populations. (nih.gov)
- Beta-blockers are established drugs in heart failure with reduced ejection fraction, but their role in heart failure with preserved ejection fraction (HFpEF) is not established. (nih.gov)
- Hence, we undertook a meta-analysis to evaluate the efficacy of beta-blockers on mortality and morbidity in HFpEF patients. (nih.gov)
- A systematic search using PubMed, Embase, Scopus and Cochrane databases was performed to identify all relevant studies on beta-blockers and HFpEF. (nih.gov)
- A random-effects model was performed to assess the role of beta-blockers on all-cause mortality and HF hospitalization. (nih.gov)
- Observational studies showed a significant benefit from the use of beta-blockers for all-cause mortality, but not for HF hospitalization. (nih.gov)
- Further large sampled well-conducted randomized trials are warranted to confirm the effects of beta-blockers on mortality and hospitalization. (nih.gov)
- They report such a case in a young woman with end-stage renal disease requiring peritoneal dialysis who was receiving antihypertensive treatment with atenolol, which unlike most beta-blockers is excreted primarily by the kidney, and which is poorly cleared by peritoneal dialysis. (medscape.com)
- Beta-blockers that are not sustained-release formulations are all rapidly absorbed from the gastrointestinal tract. (medscape.com)
- Asymptomatic intoxication occurs mainly in healthy persons with tolerance to these drugs who ingest beta-blockers that lack membrane-stabilizing effects or have a partial agonist effect (eg, pindolol). (medscape.com)
- Antihypertensive agents include diuretics, alpha-adrenergic and beta-adrenergic antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, ganglionic blockers, and vasodilator agents. (fpnotebook.com)
- However, the effect of beta- blockers and a physical training program to modulate this sympathetic activation during this valve disease is unknown. (usp.br)
- What are Adrenergic Antagonists (blockers)/ Sympatholytic Agents used for? (studystack.com)
- How do Adrenergic Antagonists (blockers)/ Sympatholytic Agents work? (studystack.com)
- What are the side effects of Adrenergic Antagonists (blockers)/ Sympatholytic Agents? (studystack.com)
- Not All Beta-Blockers Are Equal in the Management of Long QT Syndrome Types 1 and 2: Higher Recurrence of Events Under Metoprolol. (acc.org)
- Although a number of approaches (e.g., beta blockers, permanent pacing, left cervicothoracic sympathectomy, ICD implantation) have been proposed as therapeutic options for patients with the congenital long QT syndromes (LQTS), beta blocker therapy has served as the mainstay of treatment for the majority of these patients. (acc.org)
- 1-4 Furthermore, the published guidelines recommended an ICD only for LQTS patients who experience syncope or VT while taking a beta blocker (class IIa indication, level of evidence B). 5 However, there is a paucity of data on both the differential electrophysiological and clinical effects of the available beta blockers. (acc.org)
- Although clinicians often view beta blockers as similar in their pharmacological characteristics, electrocardiographic manifestations, electrophysiologic properties, and clinical efficacy, it has been established that there are a number of important differences among beta blockers. (acc.org)
- Beta blockers (sometimes written as β-blockers ) are a class of drugs used for various indications, but particularly for the management of cardiac arrhythmias and cardioprotection after myocardial infarction . (wikidoc.org)
- Whilst once first-line treatment for hypertension , their role was downgraded in June 2006 in the United Kingdom to fourth-line as they do not perform as well as other drugs, particularly in the elderly, and there is increasing evidence that the most frequently used beta-blockers especially in combination with thiazide -type diuretics carry an unacceptable risk of provoking type 2 diabetes . (wikidoc.org)
- Beta blockers inhibit these normal epinephrine-mediated sympathetic actions, but have minimal effect on resting subjects. (wikidoc.org)
- It is therefore expected that non-selective beta blockers have an antihypertensive effect. (wikidoc.org)
- The antiarrhythmic effects of beta blockers arise from sympathetic nervous system blockade - resulting in depression of sinus node function and atrioventricular node conduction, and prolonged atrial refractory periods . (wikidoc.org)
- Some beta blockers (e.g. oxprenolol and pindolol ) exhibit intrinsic sympathomimetic activity (ISA). (wikidoc.org)
- They may also be less effective than other beta blockers in the management of angina and tachyarrhythmia . (wikidoc.org)
- Intraoperative hemodynamic values were similar for the shunt and control groups as well as for patients receiving and not receiving preoperative beta blockers. (curehunter.com)
- The current study found an association between regular preoperative use of beta blockers and intraoperative cerebral ischemia in patients undergoing carotid endarterectomy . (curehunter.com)
- The systolic blood pressure increase was 3 mmHg in a subgroup of patients concomitantly prescribed angiotensin converting enzyme inhibitors or calcium channel blockers and 6 mmHg among those prescribed a beta-adrenergic blocker. (springer.com)
- Beta-blockers are medicines that work by temporarily stopping or reducing the body's natural 'fight-or-flight' responses. (medicalnewstoday.com)
- Beta-blockers are prescribed in conditions where the heart rate needs to be slowed. (medicalnewstoday.com)
- Doctors commonly recommend beta-blockers for patients with irregular heartbeats, angina, and high blood pressure. (medicalnewstoday.com)
- Beta-blockers also offer relief for glaucoma, overactive thyroid, and anxiety. (medicalnewstoday.com)
- Taking beta-blockers can cause dizziness, cold hands and feet, weight gain, and fatigue . (medicalnewstoday.com)
- Beta-blockers slow the heart beat to treat conditions in which the heart is under stress. (medicalnewstoday.com)
- Beta-blockers block the hormones adrenaline and noradrenaline in the sympathetic nervous system. (medicalnewstoday.com)
- Beta-blockers also obstruct the production of angiotensin II, a hormone produced by the kidneys. (medicalnewstoday.com)
- Beta-blockers can help to relieve the 'fight-or-flight' reactions that fuel anxiety. (medicalnewstoday.com)
- Beta-blockers block the effects of stress hormones. (medicalnewstoday.com)
- Beta-blocking agents have been less well studied for ICU delirium, although beta-blockers are known to have beneficial effects on anxiety, posttraumatic Stress Disorder (PTSD) and aggressive behavior in a variety of populations ( 16 - 20 ). (frontiersin.org)
- Beta-blockers, a class of medicines frequently used for lowering blood pressure in cardiovascular patients, have been the most commonly used agents in the first line of treatment for ocular hypertension over the past 20 years. (eurekalert.org)
- Besides being better studied than generic preparations, BETIMOL is generally well priced, especially in comparison with other branded topical beta-blockers. (eurekalert.org)
- BETIMOL is favorably priced compared to other branded beta-blockers and can be dosed one-drop-a-day once IOP is controlled. (eurekalert.org)
- adrenergic antagonists beta blockers for short. (ringaraja.net)
- Introduction CypHer ™ 5 a pH sensitive dye has shown utility in β2-adrenergic receptor agonist screening (1). (bio-medicine.org)
- CypHer5 has been used to obtain dose-response and rank-order potency data for both agonist and antagonist treatment of β2-adrenergic receptor expressing cells (2). (bio-medicine.org)
- Agonist and antagonist controls were placed symmetrically in columns 1 and 12 of each plate. (bio-medicine.org)
- Twelve replicate wells contained a known agonist, isoproterenol, and four replicate wells contai ned a known antagonist, alprenolol, each diluted in 0.01% DMSO. (bio-medicine.org)
- Synonyms : 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol, 1-(Isopropylamino)-3-[P-(cyclopropylmethoxyethyl)phenoxy]-2-propanol, Betaxololum Status : approved Antihypertensive Agents BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists A cardioselective beta-1-adrenergic antagonist with no partial agonist activity. (pharmakb.com)
- In a small placebo-controlled trial, the beta-2 agonist albuterol improved lean body mass in boys with DMD, but there were no significant improvements in manual muscle tests and other measures of physical functioning. (lww.com)
- Lead investigator Melissa J. Spencer, PhD, associate professor of neurology at the David Geffen School of Medicine at the University of California-Los Angeles, said the findings suggest that albuterol, a beta-2 adrenegic agonist and an FDA-approved drug for asthma, might also help retain muscle tissue in boys with DMD. (lww.com)
- Importance of Alpha - adrenergic Receptor Subtypes in Regulating of Airways Tonus at Patients with Bronchial Asthma In this work, effect of Tamsulosin hydrochloride as antagonist of alpha1A and alpha1B- adrenergic receptor and effect of Salbutamol as agonist of beta2- adrenergic receptor in patients with bronchial asthma and increased bronchial reactibility was studied.Parameters of the lung function are determined by Body plethysmography. (tripdatabase.com)
- Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. (springer.com)
- These agents are capable of exerting low level agonist activity at the β-adrenergic receptor while simultaneously acting as a receptor site antagonist . (wikidoc.org)
- Dexmedetomidine is a potent alpha-2 adrenergic agonist that binds to the alpha-2 adrenergic receptor subtype A at the LC, resulting in almost complete inhibition of the LC, which has a sedative effect ( 5 , 6 ). (frontiersin.org)
- A cardioselective beta-1-adrenergic antagonist with no partial agonist activity. (drugbank.ca)
- Potent, selective β 3 adrenoceptor antagonist (IC 50 values are 40, 408 and 648 nM for β 3, β 1 and β 2 , respectively). (abcam.com)
- Adrenergic beta-antagonists are used for treatment of Hypertension , Cardiac Arrhythmias , Angina Pectoris , Glaucoma , Migraine Headaches , and Anxiety . (online-medical-dictionary.org)
- Among categorical data, in addition to the epidemiological variables such as age and sex, we considered factors related to arterial and portal hypertension: we therefore evaluated the recipient gender, the presence in the medical history of previous surgery or a TACE (transarterial chemo-embolization), arterial hypertension, antihypertensive therapy, beta-blocker therapy, oesophageal varices, the type of liver disease, and the type of viral liver disease (hepatitis B and C). (plos.org)
- Beta-adrenergic antagonists are appropriate in the treatment of ocular hypertension in many patients with the condition," stated Dr. Singh. (eurekalert.org)
- The survey was sponsored by Santen Incorporated, the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. Santen's BETIMOL (timolol ophthalmic solution) 0.25%, 0.5% is a beta-blocker (non-selective beta-adrenergic antagonist) medication indicated for the treatment of elevated IOP in patients with ocular hypertension or open-angle glaucoma. (eurekalert.org)
- A non-selective beta-adrenergic antagonist … A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. (neurolex.org)
- Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. (pharmacycode.com)
- Many ideal patients for beta-blocker therapy are not prescribed these drugs at discharge following AMI. (nih.gov)
- The beta-adrenoblockers anapriline and visken and the calcium antagonist corinfar were studied for effects on the atherogenic properties of the sera from patients with coronary heart disease who took the drugs. (inat.ru)
- beta-blocking drugs may cause hypoglycemia by inhibiting glycogenolysis. (medscape.com)
- Beta-adrenergic blocking drugs. (ringaraja.net)
- The recommended dosage depends on the type, strength, and form of beta blocker and the condition for which it is prescribed. (encyclopedia.com)
- Of the 36795 patients who were not receiving beta-blocker therapy on admission, 16006 (43.5%) had therapy initiated on or before discharge. (nih.gov)
- Demographic and clinical variables explained relatively little of the variation in the initiation of beta-blocker therapy. (nih.gov)
- The New England region had significantly higher use of beta-blocker therapy than the rest of the country. (nih.gov)
- However, in the two RCTs, the use of beta-blocker was not associated with all-cause mortality [RR 0.94 (0.67-1.32), p = 0.or HF hospitalization [0.90 (0.54-1.49), p = 0. (nih.gov)
- Ideally, the clinician should determine the specific beta-blocker involved, the quantity, and the time of the overdose. (medscape.com)
- When a history of intentional overdose is lacking, beta-blocker toxicity can go unrecognized as a cause of bradycardia and hypotension. (medscape.com)
- Hoot et al note the risk of chronic beta-blocker toxicity in patients with impaired clearance. (medscape.com)
- If a patient is bradycardic and hypotensive, the clinician should consider a beta-blocker or calcium channel blocker overdose . (medscape.com)
- Myocardial conduction delays with decreased contractility typify the acute beta-blocker ingestion. (medscape.com)
- In all clinically significant beta-blocker overdoses, symptoms develop within 6 hours. (medscape.com)
- Conversely, circulatory collapse may occur in patients with preexisting cardiac failure when sympathetic drive is inhibited by even a small dose of a particular beta-blocker. (medscape.com)
- 60 bpm) defines severe beta-blocker toxicity. (medscape.com)
- Beta Blocker (e.g. (fpnotebook.com)
- Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. (springer.com)
- In follow-up, the risk reduction for a BCE was correlated with greater QTc shortening on beta blocker therapy. (acc.org)
- A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). (nih.gov)
- These agents, therefore, may be useful in individuals exhibiting excessive bradycardia with sustained beta blocker therapy. (wikidoc.org)
- Preoperative beta blocker use associated with cerebral ischemia during carotid endarterectomy. (curehunter.com)
- P = 0.005) for the association between use of a beta blocker and shunting. (curehunter.com)
- There are many different brands of beta-blocker. (medicalnewstoday.com)
- The high pressure within the eyeball is reduced using beta-blocker eye drops. (medicalnewstoday.com)
- The objective of this study is to establish how best to reverse the short term effects of a single dose of beta blocker. (bioportfolio.com)
- BETIMOL is the only branded formulation of timolol hemihydrate, a topically applied ophthalmic beta-blocker. (eurekalert.org)
- Its efficacy and safety have been shown to be equivalent to the leading product in the beta-blocker category. (eurekalert.org)
- Equally, the similarity in the symptomatic, circulatory, and electrocardiographic response to the intravenous and oral preparations suggests that metabolic breakdown products are probably of therapeutic importance only in so far as they antagonize beta-receptor activity. (bmj.com)
- Animal and human evidence indicates a potential therapeutic benefit for β-adrenergic receptor antagonists, selective cyclooxygenase inhibitors, and anti-fibrinolytics administered through the perioperative period. (edu.au)
- Selective alpha and beta 1 and beta 2 adrenergic antagonists were used with electrical stimulation of the sympathetic innervation to parotid and submandibular glands of rats in order to delineate the role of the beta 1 and beta 2 adrenoceptors in regulation of salivary flow rate, Na reabsorption and K secretion from these glands. (mysciencework.com)
- ß(3) adrenergic stimulation of the cardiac Na+−K + pump by reversal of an inhibitory oxidative modification. (springer.com)
- Acute and chronic intrarenal alpha- and beta- adrenergic receptor stimulation of renin release in the conscious dog. (ahajournals.org)
- Absolute peak exercise capacity was a stronger predictor of the risk of death than the percentage of the age-predicted value achieved, and there was no interaction between the use or nonuse of beta-blockade and the predictive power of exercise capacity. (nih.gov)
- Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha - adrenergic Blockade Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha - adrenergic Blockade - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. (tripdatabase.com)
- The second rise in PRA was increased by 30% with alpha-adrenergic blockade. (ahajournals.org)
- Synonyms : (+-)-1-((alpha-(2-Isopropoxyethoxy)-P-tolyl)oxy)-3-(isopropylamino)-2-propanol, (RS)-1-(4-(2-isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol, Bisoprolol, Bisoprololum Status : approved Antihypertensive Agents BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists Bisoprolol is a cardioselective β1-adrenergic blocking agent used for secondary prevention of myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. (pharmakb.com)
- Synonyms : (+-)-Practolol, 1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol, 4′-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide, N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide, Practololum, Tocris-0831 Status : approved Adrenergic beta-1 Receptor Antagonists BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Anti-Arrhythmia Agents A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias. (pharmakb.com)
- Synonyms : (RS)-Metoprolol, 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol, Metoprolol Status : approved Antihypertensive Agents BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists Metoprolol is a cardioselective β1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. (pharmakb.com)
- Mechanism of action: Like other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. (neurolex.org)
- beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. (springer.com)
- Beta-2 adrenergic receptor activation also appears to be important in the MSA and MPOA, resulting in dose-dependent increases in time spent awake ( 4 ). (frontiersin.org)
- Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes. (abcam.com)
- Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical beta adrenocepto. (biomedsearch.com)
- Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. (abcam.com)
- For this reason, beta-adrenergic antagonists may be used to relieve symptoms. (washington.edu)
- In hyperthyroidism, adrenergic hyperactivity is a major cause of psychiatric symptoms, and beta-adrenergic antagonists are effective treatment. (medscape.com)
- The data demonstrate that the β2-adrenergic receptor CypHer5E antagonist assay used in conjunction with IN Cell Analyzer 1000 was able to identify all specific β2-adrenergic receptor antagonists and additional structurally related compounds present in the LOPAC compound library. (bio-medicine.org)
- Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action. (pharmacycode.com)
- Patients had no history of esophageal varices, variceal bleeds, or treatment with beta-adrenergic antagonists prior to their index date. (thefreedictionary.com)
- Although cardiac failure rarely occurs in properly selected patients, patients being treated with beta-adrenergic blocking agents should be advised to consult the physician at the first sign or symptom of impending failure. (pharmacycode.com)
- H 1 receptor antagonist any of a large number of agents that block the action of histamine by competitive binding to the H 1 receptor. (thefreedictionary.com)
- Beta-adrenergic blocking agents, beta-adrenergic antagonists, or beta antagonists. (wikidoc.org)
- They are also sometimes known as beta antagonists, beta-adrenergic blocking agents, or beta-adrenergic antagonists. (medicalnewstoday.com)
- The relationship between beta-adrenoceptors and adrenergic responsiveness in trout (Oncorhynchus mykiss) and eel (Anguilla rostrata) erythrocytes. (semanticscholar.org)
- Rabbit, a relevant model for the study of cardiac beta 3-adrenoceptors. (springer.com)
- Effects of alpha, beta 1, and beta 2 adrenergic antagonists on. (mysciencework.com)
- Effects of alpha, beta 1, and beta 2 adrenergic antagonists on the Na and K concentrations of sympathetic-nerve stimulated rat saliva. (mysciencework.com)
- α-adrenergic antagonist alpha-adrenergic blocking agent . (thefreedictionary.com)
- Alpha- or beta-adrenergic antagonists did not attenuate the initial rise in PRA. (ahajournals.org)
- This increase in PRA was blocked by phentolamine, suggesting a vascular alpha-adrenergic receptor-mediated release of renin. (ahajournals.org)
- At the end of the chronic isoproterenol infusion period, beta-adrenergic receptor refractoriness was demonstrated, as PRA did not increase significantly in response to a fourfold increase in the dose of isoproterenol. (ahajournals.org)
- Isoproterenol and aminophylline may or may not even level in your body adjusts beta-adrenergic autonomic system. (ringaraja.net)